Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer:A phase III, randomised, multicentre trial (Ovaresist) by Lindemann, Kristina et al.
Syddansk Universitet
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer
A phase III, randomised, multicentre trial (Ovaresist)
Lindemann, Kristina; Gibbs, Emma; Åvall-Lundqvist, Elisabeth; Christensen, René dePont;
Woie, Kathrine; Kalling, Marten; Auranen, Annika; Grenman, Seija; Hoegberg, Thomas;
Rosenberg, Per; Skeie-Jensen, Tone; Hjerpe, Elisabet; Dørum, Anne; Gebski, Val;
Kristensen, Gunnar
Published in:
British Journal of Cancer
DOI:
10.1038/bjc.2016.435
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-SA
Citation for pulished version (APA):
Lindemann, K., Gibbs, E., Åvall-Lundqvist, E., Depont Christensen, R., Woie, K., Kalling, M., ... Kristensen, G.
(2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: A phase III, randomised, multicentre
trial (Ovaresist). British Journal of Cancer, 116(4), 455-463. DOI: 10.1038/bjc.2016.435
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Sep. 2018
Chemotherapy vs tamoxifen in
platinum-resistant ovarian cancer: a phase III,
randomised, multicentre trial (Ovaresist)
Kristina Lindemann*,1,2,3, Emma Gibbs4, Elisabeth Åvall-Lundqvist5,6, Rene dePont Christensen7,
Kathrine Woie8, Marten Kalling9, Annika Auranen10, Seija Grenman11,12, Thomas Hoegberg13,
Per Rosenberg14, Tone Skeie-Jensen1, Elisabet Hjerpe7, Anne Dørum1, Val Gebski4 and Gunnar Kristensen1,15
1Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 2NHMRC Clinical
Trials Centre, University of Sydney, Camperdown, NSW, Australia; 3Department of Medical Oncology, Westmead Hospital, Crown
Princess Mary Cancer Centre, Wentworthville, NSW, Australia; 4NHMRC Clinical Trials Centre, University of Sydney, Camperdown,
NSW 2050, Australia; 5Department of Oncology and Department of Clinical and Experimental Medicine, Linko¨ping University,
Linko¨ping, Sweden; 6Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; 7Research Unit of
General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark; 8Department of Gynecologic
Oncology, Haukeland University Hospital, Bergen, Norway; 9Department of Gynecologic Oncology, Skane University Hospital,
Lund, Sweden; 10Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland; 11Department of
Obstetrics and Gynecology, Turku University Hospital, Turku, Finland; 12University of Turku, Turku, Finland; 13Department of
Cancer Epidemiology, Skane University Hospital Lund, Lund, Sweden; 14Department of Oncology, Linko¨ping University Hospital,
Linko¨ping, Sweden and 15Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo and University of Oslo,
Oslo, Norway
Background: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free
survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and
tamoxifen in PROC.
Methods: Patients with PROC were randomised (2 : 1) to chemotherapy (weekly paclitaxel 80mgm 2 or four weekly pegylated
liposomal doxorubicin 40mgm 2) or tamoxifen 40mg daily. The primary end point was HRQoL. Secondary end points were PFS
by RECIST and overall survival (OS).
Results: Between March 2002 and December 2007, 156 and 82 patients were randomised to chemotherapy and tamoxifen,
respectively. In the chemotherapy arm, a significantly larger proportion of patients experienced a worsening in their social
functioning. There was no difference in the proportion of patients experiencing improvement of gastrointestinal symptoms.
Median PFS on tamoxifen was 8.3 weeks (95% CI, 8.0–10.4) compared with 12.7 weeks (95% CI, 9.0–16.3) on chemotherapy (HR,
1.54; 95% CI, 1.16–2.05; log-rank P¼ 0.003). There was no difference in OS between the treatment arms.
Conclusions: Patients on chemotherapy had longer PFS but experienced more toxicity and poorer HRQoL compared with
tamoxifen. Control over gastrointestinal symptoms was not better on chemotherapy. These data are important for patient
counselling and highlight the need to incorporate HRQoL end points in studies of PROC.
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Chemotherapy for patients with recurrent ovarian cancer remains
palliative, with the aim to improve quality of life and prolong
time to progression. The platinum-free interval is of predictive
significance as responses to re-exposure to platinum are less likely
with shorter time since last platinum-based chemotherapy (Gore
et al, 1990; Markman et al, 1991). Ultimately, most patients with
recurrent disease will develop platinum resistance. In this setting,
combination therapies are associated with increased toxicity
without advantage in overall survival (OS) (Buda et al, 2004;
Sehouli et al, 2008; Lortholary et al, 2012), and single-agent
therapies have been favoured. The most active agents are pegylated
liposomal doxorubicin (PLD), weekly paclitaxel, gemcitabine and
topotecan (ten Bokkel Huinink et al, 1997; Gordon et al, 2001;
Mutch et al, 2007; Vergote et al, 2010) with response rates between
8.3 and 21%. Only recently the combination of bevacizumab and
single-agent chemotherapy has been reported to significantly
increase progression-free survival (PFS) compared with che-
motherapy alone (Pujade-Lauraine et al, 2014). Still, treatment
with chemotherapy is associated with side effects like neutropenia,
alopaecia, neuropathy and palmar-plantar erythrodysesthesia
(PPE) and these have been shown to impair patient’s quality of
life (Lakusta et al, 2001; Stiggelbout and de Haes, 2001; Le et al,
2004). Hormonal treatment has been considered a worthwhile
alternative to chemotherapy due to its limited side effects and
simple dosing. The antitumour activity of tamoxifen is believed to
be mediated by competitive binding to oestrogen receptors, but a
direct antiproliferative effect of oestrogen antagonists and
progesterone has also been suggested (Batra and Iosif, 1996). To
our knowledge, there is to date only one comparative study of
endocrine treatment (leuprorelin) vs chemotherapy (treosulfan)
(du Bois et al, 2002). This study was stopped prematurely due to
concerns about the lack of efficacy. For tamoxifen, phase II studies
have reported response rates around 10–13% (Markman et al,
1996; Williams et al, 2010) with stabilisation of disease in 32% of
the patients, which is not dissimilar to the results of chemotherapy
in this population (Hatch et al, 1991).
In the context of platinum-resistant ovarian cancer (PROC), the
trade-offs between clinical benefit and quality of life are important
and the performance of tamoxifen against chemotherapy in this
patient group has not been previously investigated in a phase III
setting.
This is a phase III randomised study comparing single-agent
chemotherapy with tamoxifen in patients with PROC. Preliminary
results were presented at the 2008 Annual Meeting of the
American Society of Clinical Oncology.
PATIENTS AND METHODS
The study was designed and carried out in accordance with good
clinical practice, the declaration of Helsinki and national laws.
Local ethics committee of each participating centre approved the
study. All patients provided written informed consent before study
entry. The study is registered at ClinicalTrials.gov with Identifier:
NCT02728622.
Eligibility criteria, randomisation and quality assurance.
Patients with histologically confirmed invasive epithelial ovarian,
fallopian tube or peritoneal cancer, being resistant to treatment
with platinum and a taxane (in a three-weekly regimen), either
given in combination or sequentially, were eligible. Resistance was
defined as one of the following. (1) Clinical progression during or
within 6 months after end of treatment for primary disease or
relapse. (2) Stable disease after six courses of chemotherapy for
primary disease or relapse. (3) Doubling of CA 125 to at least
70 IUml 1 within 3 months after end of treatment for primary
disease or relapse.
Patients were to be aged X18 years, have ECOG performance
status p2, and have adequate liver, renal and bone marrow
function. Exclusion criteria were symptomatic brain metastases,
active infection or other severe underlying medical condition.
Randomisation was performed by computerised minimisation
techniques. Patients were randomised 1 : 2 to either hormonal
treatment or chemotherapy of investigator’s choice.
The responsible study office (NSGO-CTU) followed the
protocol-defined guidelines on central monitoring and reviewed
case report forms for completeness and consistency.
Treatment plan and dose modifications. Patients randomised to
hormonal treatment received oral tamoxifen 40mg daily. Patients
randomised to chemotherapy received either paclitaxel 80mgm 2
as a 1-h infusion, given every 7 days or PLD 40mgm 2 given
every 4 weeks. The first dose was infused over 2 h; later doses were
infused over 1 h. Chemotherapy was administered with appropriate
premedication.
Study specific guidelines were followed for dose delay and dose
reduction for haematologic and non-haematologic toxicity and for
supportive care use.
The use of supportive G-CSF treatment was not recommended
instead of dose reduction but was left to the investigator’s
discretion.
Assessment of PROs, efficacy and follow-up. Health-related
Quality of Life (HRQoL) was evaluated using the European
Organization for Research and Treatment of Cancer (EORTC)
quality-of-life questionnaire (QLQ-C30, version 3.0) and the
specific module for ovarian cancer (QLQ-OV-28, version 1.0).
Health-related Quality of Life was assessed at baseline and every 8
weeks (±2 weeks) during treatment and every 12 weeks (±2
weeks) thereafter until patient death or withdrawal. In this analysis,
questionnaires from all assessments until disease progression were
analysed.
Tumour measurements according to Response Evaluation
Criteria in Solid Tumors (RECIST) (Therasse et al, 2000) were
recorded at baseline and every 8 weeks using the same tumour
assessment technique throughout the study. Treatment was
discontinued in case of clinical tumour progression or deteriora-
tion of performance status not being compatible with continued
treatment. In case of complete clinical remission, treatment could
be terminated after two more courses of PLD or six more courses
of paclitaxel.
In case of progression on protocol treatment, a crossover from
tamoxifen to chemotherapy and from chemotherapy to tamoxifen
was recommended if continued treatment was in the best interest
of the patient.
Adverse events and toxicity were graded during each cycle by
the study investigator according to the National Institute Common
Toxicity Scale version 1.0 (Cancer Therapy Evaluation Program,
1992). Toxicities were evaluated using the worst score per toxicity
in each patient.
Date of last follow-up was the 5 January 2009.
Statistical analyses. The primary end point was evaluation of
HRQoL in both treatment arms. Secondary end points were PFS
and OS.
The study was designed in 2002 when detailed aspects of
HRQoL outcomes and sample size were described in general rather
than in specific terms in the protocol. As the analysis of the
primary end point HRQoL was not adequately prespecified in the
protocol, the results presented here are considered secondary
analyses. Nevertheless, the study was conducted to investigate
whether the less toxic but potentially less effective treatment with
tamoxifen would demonstrate an improvement in HRQoL
compared with the presumably more toxic treatment with
chemotherapy. In exploratory analyses of HRQoL, we assessed
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quality-adjusted survival (QAS) as a measure to address this
research question.
In the original protocol, the sample size for the study was based
on detecting a difference in HRQoL and also in PFS, with no
adjustment for type I error. The power calculation for HRQoL was
based on detecting an improvement of 1 point on the 7-point
Likert scale; however, the version of QLQ-C30 used in the study
did not present items on a 7-point Likert scale. For PFS, it was
powered to detect at least a 54% increase in the risk of progression
(hazard ratio (HR) of 1.54) on tamoxifen assuming a median time
to progression of 13 weeks for those receiving tamoxifen and 20
weeks for those receiving chemotherapy. Based on a 2 : 1
randomisation, a 3-year accrual and 1-year follow-up, a sample
size of 223 patients was required to detect this difference. Power
calculation should ideally have been based on the primary end
point, change in HRQoL, alone.
PFS was defined as the time from randomisation to disease
progression or death from any cause. Overall survival was defined
as the time from randomisation to death from any cause. Response
was recorded as best response on treatment.
Efficacy and HRQoL analyses were based on the intent-to-treat
population of eligible patients. Analysis of toxicities was based on
the safety population (all patients who received at least one dose of
study treatment). The scoring manuals from EORTC were applied
to the HRQoL data to calculate scales for each instrument (Fayers
et al, 2001). The abdominal/gastrointestinal (GI) symptom
subscale comprised items 1–6 of the EORTC QLQ-OV28. The
chemotherapy side effects subscale comprised items 13–17 and
hormonal side effects items 18 and 19. Compliance of HRQoL was
calculated using all patients, who had not progressed or died prior
to the time point as the denominator.
All analyses of HRQoL questionnaires were performed using a
mixed model for repeated measures with time by treatment
interaction, together with the appropriate baseline scores, treat-
ment allocation and time point. HRQoL subscales were presented
for patients up to 30 days after their end of treatment day. HRQoLs
were reassigned a visit based on the date of completion. On
treatment this was any QoL within an 8 week window.
For the QAS analysis, the weights of McKenzie (McKenzie and
van der Pol, 2009) were applied to the QLQ-C30 to estimate EQ5D
utility. Survival probabilities were calculated using the area under
the curve with an appropriate truncation time point of 43 weeks.
An estimation of the QAS was calculated with a 95% CI and
P-value using bootstrapping methods with a 1000 replications. As
visits were scheduled every 12±2 weeks, QAS included all patients
with at least one HRQoL measurement 12þ 2 weeks prior to the
date of progression or 12þ 2 weeks after if no HRQoL prior to PD
was available.
In responder analysis we studied the proportion of patients with
a clinically significant change in HRQoL score on a particular scale
compared with their baseline score. An improvement was defined
as at least 15% increase with a 10% increase used in sensitivity
analysis (Osoba et al, 2005; Stockler et al, 2014). Patients with a
HRQoL decrease of 15% or more (10% in sensitivity analysis) were
classified as ‘worsened’, whereas a change within those ranges was
classified as ‘no change’. Chi-square test was used to determine the
statistical significance of differences between the treatment arms.
Subgroup analysis was performed for the GI symptom scale in
relationship to patients’ severity of GI symptoms at baseline.
Category boundaries were determined using median score at
baseline for the dividing patients into those with high and low
baseline symptoms.
Enrolment
Assessed for eligibility (n=241)
Excluded (n=3)
♦ Not meeting inclusion criteria (n=1)
♦ Declined to participate (n=1)
♦ Other reasons (n= 1)
Randomised (n=238)
Allocation
Analysis ITT
Analysis Safety
population
Allocated to chemotherapy (n=156)
♦ Received allocated intervention (n=154)
♦ Did not receive allocated intervention
Allocated to Tamoxifen (n=82)
♦ Received allocated intervention (n=79)
♦ Did not receive allocated intervention
(refused allocated treatment, incomplete
records in the database) (n=3)
Analysed (n=156)
Analysed (n=154)
Analysed (n=82)
Analysed (n=79)
(violation of inclusion criteria, clinical
deterioration) (n=2)
Figure 1. CONSORT diagram: enrolment, randomization and treatment.
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Time-to-event data were analysed using the Kaplan–Meier
method, and the log-rank test was used to compare the
distributions between groups. Hazard ratios with 95% CIs were
estimated using the Cox proportional hazards model. Sensitivity
analysis used a stratified log-rank test stratifying for the a priori
defined factor of progression during or after discontinuation of
chemotherapy.
Toxicity was described for each group separately and propor-
tions compared by the Wilcoxon–Mann–Whitney test.
SAS statistical package, version 9.3, was used for the analysis.
Plots were created in Stata 13.0.
RESULTS
Patients and follow-up. Between March 2002 and December
2007, 241 patients were enrolled. Three patients were excluded
from the intention-to-treat population. One patient was excluded
due to evident brain metastases, one patient had no data ever
recorded, and a third patient was randomised twice under two
different ID numbers. Two-hundred and thirty-eight patients were
included in the intention-to-treat analysis of eligible patients, 82 in
the tamoxifen arm and 156 in the chemotherapy arm (Figure 1). Of
the patients randomised to chemotherapy, 70 were allocated to
weekly paclitaxel and 86 to PLD. Five patients did not receive the
allocated treatment: two patients in the chemotherapy arm and
three allocated to tamoxifen. Thus, 233 patients were included in
the safety analysis. Baseline characteristics are summarised in
Table 1. The CONSORT diagram for the population analysed for
quality of life is shown in Supplementary Figure S1. The
compliance rates with HRQoL assessments in the tamoxifen arm
were 85% (47 of 55) and 72% (23 of 32) at weeks 8 and 16,
respectively. In the chemotherapy arm, these rates were 89% (119
of 133) and 77% (65 of 84), respectively. For analysis of QAPFS, 2
patients had no QoL information 12þ 2 weeks prior to PD and
thus had QoLs included 4 and 10 days after PD. Median follow-up
was 169 weeks (range: 0–326).
Toxicity. There was a statistically significant difference in non-
haematological and haematological toxicities between the treat-
ment arms with more nausea, mucositis, motor neuropathy,
neurosensory, PPE, anaemia, leukopenia and neutropenia
(Supplementary Table S1) in the chemotherapy arm. Two patients
had febrile neutropenia in the chemotherapy arm, none in the
tamoxifen arm. Patients on PLD had significantly more nausea,
mucositis and PPE, but less anaemia compared with paclitaxel. In
the chemotherapy arm, 4 (2.6%) patients received G-CSF and 12
patients (7.8%) experienced a dose reduction. Of the four dose
reductions on paclitaxel, three were due to haematological toxicity
(neutropenia and thrombocytopenia). On PLD, eight patients had
a reduction in dose, seven due to non-haematological toxicity
(PPE) and one due to haematological reasons (neutropenia). In 37
patients (24%) chemotherapy was delayed for at least one cycle. In
the tamoxifen arm, eight patients (10.1%) had a loss in treatment
days, ranging from 1 to 52 days.
Deaths on study. Ten (6.4%) patients died in the chemotherapy
arm; seven of those were related to the disease. One patient died
due to sepsis of unknown origin, and one developed headache and
became unconsciousness before she died. No autopsy was
performed. The third patient was admitted to hospital with a
subarachnoid haemorrhage and died the next day. Eight (10.1%)
deaths occurred on tamoxifen, with seven being disease related.
One patient died of sepsis of unknown origin.
Efficacy. A total of 203 patients (85.3%) had progressive disease
during follow-up. Median PFS in the tamoxifen group was 8.3
weeks (95% CI, 8.0–10.4) compared with 12.7 weeks (95% CI,
9.0–16.3) in the chemotherapy arm, corresponding to a HR of 1.54
(95% CI, 1.16–2.05; log-rank P¼ 0.003) (Figure 2). There was no
statistically significant difference in PFS between the two
chemotherapy arms (HR of 1.21, 95% CI: 0.85–1.72).
By the end of follow-up, 204 (85.7%) patients had died. Median
OS time was 44.9 weeks (95% CI, 31.1–57.7) in the tamoxifen arm
and 46.9 weeks (95% CI, 37.1–51.0) in the chemotherapy arm,
corresponding to a HR of 1.10 (95% CI, 0.82–1.47; log-rank
P¼ 0.53) (Figure 2). Stratification for type of prior progression did
not affect the estimates of PFS or OS.
Two hundred patients (84%) (136 in the chemotherapy arm and
64 in the tamoxifen arm) were evaluable and assessed for response.
Of those, 2 patients (1.5%) experienced complete response and 21
(15.4%) partial response in the chemotherapy arm. In the
tamoxifen arm, the best response obtained was partial response
in three patients (4.7%). Stable disease was achieved in 52 patients
(38.2%) in the chemotherapy arm and 20 (31.3%) in the tamoxifen
arm. Progression was reported in 61 (44.9%) and 41 patients
(64.1%) in the chemotherapy arm and tamoxifen arm, respectively.
Table 1. Baseline characteristics
Chemotherapy
(N¼156)
Tamoxifen
(N¼82)
Characteristics
No. of
patients %
No. of
patients %
Age, years
Mean 61.7 62.1
95% CI (60.3, 63.1) (60.1, 64.1)
FIGO stage
I 11 7 5 6
II 7 4 1 1
III 98 63 55 67
IV 40 26 21 26
Tumour type
Ovarian cancer 136 87 76 93
Peritoneal cancer 15 10 4 5
Tubal cancer 5 3 2 2
Histology
Serous 106 68 71 87
Mucinous 6 4 0 0
Clear cell 10 6 1 1
Endometrioid 15 10 2 2
Undiff. 5 3 2 2
Unclass. 2 1 2 2
Other 12 8 3 4
Unknown 0 0 1 1
Grade
Well diff. 3 2 9 11
Mod. diff. 34 22 15 18
Poor diff. 101 65 49 60
Unknown 17 11 9 11
Missing 1 1 0 0
Performance status
0 96 62 43 52
1 53 34 37 45
2 7 4 2 2
Type of progression
Progression during treatment 10 6 6 7
Progression within 3 months of end
of treatment
90 58 38 46
Progression between 3 and 6
months of end of treatment
56 36 38 46
Number of previous lines of chemotherapy
1 86 55 52 63
2 53 34 18 22
43 17 11 12 15
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Mean quality-of-life scores over time adjusted for the baseline.
Over the study period, there was no statistical difference between
the two arms for all the functioning scales (Figure 3). A statistically
significant difference between the two arms existed at week 16 only
for the abdominal GI symptom (P¼ 0.04) and hormonal side
effects (P¼ 0.01) subscales, with more symptoms in the tamoxifen
arm. Chemotherapy side effects symptoms were more common in
the chemotherapy arm; however, the difference did not reach
statistical significance.
Patient response analysis. Figure 4 illustrates the responder
analysis (improved, stable or worsened) for each HRQoL scale
and at week 8 based on a change of 15%. In the chemotherapy
arm, a significantly larger proportion of patients experienced
a worsening in their social functioning at week 8. For a change
in HRQoL of 10% significantly more patients reported a worsening
in both their social and physical functioning on chemotherapy
compared with patients on tamoxifen (Supplementary Figure S2).
The majority, 200 (90.9%), reported abdominal symptoms at
baseline with a median symptom score of 22.2. There was no
difference in the proportion of patients who reported improvement
of their GI symptoms between the treatment arms. There was
further no statistical significant difference between the treatment
arms in the proportion of patient with symptom improvement in
subgroups of more or less GI symptoms at baseline.
Quality-of-life adjusted survival. Table 2 includes the quality-
adjusted survival estimates for PFS. There was a significant
difference between the utilities in favour of tamoxifen. However,
this difference was offset by the difference in PFS and thus there
was no difference in quality-adjusted PFS between the treatment
arms (P¼ 0.14).
DISCUSSION
In this study of patients with PROC, single-agent chemotherapy
was more effective in prolonging PFS compared with tamoxifen,
but this small gain was traded off against poorer quality of life
and increased treatment-related toxicity. Treatment with chemo-
therapy did not yield better control over GI symptoms compared
with tamoxifen. There was no difference in OS between the
treatment arms.
Our survival data in patients treated with single-agent
chemotherapy are disappointing but in line with most previous
reports (ten Bokkel Huinink et al, 1997; Gordon et al, 2001; Mutch
et al, 2007; Vergote et al, 2010). Only about 17% of the evaluable
patients showed complete or partial response on chemotherapy.
Similar response rates have previously been reported for tamoxifen
in PROC (Markman et al, 1996). Tamoxifen has not previously
been directly compared with single-agent chemotherapy in PROC.
A randomised study on the alkylating agent treosulfan and the
GnRH (gonadotropin-releasing hormone) analoga leuprorelin
reported no objective response in either of the treatment arms
but significantly longer PFS in the chemotherapy arm (17 weeks vs
10 weeks, P¼ 0.035). In our study only 4.7% responded to
tamoxifen. Even though chemotherapy yielded better response
rates than tamoxifen, the median PFS just exceeded 3 months.
Patients on chemotherapy experienced more haematological
and non-haematological toxicities and a deterioration of their
social and physical functioning during treatment. We also
studied the potential palliative effect of chemotherapy on GI
symptoms as HRQoL data from second-line treatment
with platinum-based chemotherapy suggested better symptomatic
control especially in symptomatic patients (Brundage et al, 2012).
The proportion of patients reporting GI-symptom improvement
here was the same in both treatment arms, also in patients with
higher symptom burden at baseline, suggesting that single-agent
chemotherapy is not better than tamoxifen in palliating these
symptoms. There is evidence that patients can accept a more toxic
regimen if a benefit in survival is expected (Lee et al, 2013). In this
study, we tried to assess these trade-offs by analysing QAPFS.
There was no difference in QAPFS between the treatment arms,
which may mean that the small gain in PFS was traded off against
the poorer quality of life on chemotherapy.
The strengths of this study include its randomised design, the
assessment of response and progression by RECIST criteria and the
high completeness rate of HRQoL data until progression. There are
several limitations of this study. The analysis of the primary end
point of this study, HRQoL, was poorly defined in the protocol.
Still, the primary and prespecified research question was to
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Figure 2. Kaplan–Meier estimates of progression-free and OS according to treatment arm.
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evaluate quality of survival with either of the regimens. We can
therefore interpret the effects of the regimens on the quality-of-life
outcomes as assessed here but need to be cautious to conclude
from analyses of QAPFS as they may be underpowered. The higher
completion rate of HRQoL assessments in the chemotherapy arm
may also have biased our results. There was no evaluation of
hormone receptor status and better patient selection to endocrine
treatment may have led to better outcomes on tamoxifen treatment
(Hatch et al, 1991). Also, the time to first response assessment may
have been too short to observe an antiprofilerative effect. In the
chemotherapy arm patients with unfavourable baseline character-
istics were overrepresented. The patients had more previous lines
of chemotherapy and more mucinous and clear-cell tumour
histologies, which are known to be less chemosensitive compared
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BRITISH JOURNAL OF CANCER Chemotherapy vs tamoxifen in PROC
460 www.bjcancer.com |DOI:10.1038/bjc.2016.435
with other histologies. These differences may have contributed to
the slightly poorer results when compared with the results in the
chemotherapy arm of the Aurelia study (Pujade-Lauraine et al,
2014). We could not demonstrate any benefit in OS for patients
treated with chemotherapy probably in part due to the allowance of
crossover between the trial arms post-progression. The tamoxifen
and chemotherapy arms, 77 and 62%, respectively, received further
chemotherapy. Subsequent treatment after progression may also
have had an impact on our estimates of HRQoL at progression as
these data in a minority of patients were collected after
progression.
Since the study was designed, treatment strategies of platinum-
resistant disease have evolved. The combination of single-agent
chemotherapy with bevacizumab has been shown to increase
response rates and PFS compared with single-agent chemotherapy
alone, also with a benefit for GI symptoms (Pujade-Lauraine et al,
2014; Stockler et al, 2014). There was also a marginally significant
benefit in OS in patients who had received paclitaxel plus
bevacizumab (Poveda et al, 2015). However, due to the strict
exclusion criteria with regard to the increased risk of GI
perforation on bevacizumab, these findings may not be gener-
alisable to all patients with PROC. Funding restrictions in many
countries are another reason why single-agent chemotherapy is still
widely used. There is also growing evidence that a subgroup of
patients may again respond to platinum-based chemotherapy
despite short disease-free survival. Especially patients with germ-
line-BRCA mutation, but possibly also patients with somatic
mutations in the DNA homologous repair pathway, may be more
likely to respond to re-challenge with carboplatin and thus yield
longer PFS (Alsop et al, 2012) compared with non-platinum
based chemotherapy. Strategies targeting that pathway directly
(i.e., PARP inhibitors) have also shown promising results in PROC
(Kaufman et al, 2015) with a more favourable toxicity profile
compared with chemotherapy.
In this phase III study in PROC a more toxic but presumably
more effective treatment (single-agent chemotherapy) is compared
with a potentially less toxic one (tamoxifen). The marginal longer
PFS on chemotherapy was traded off against poorer quality of life
questioning the palliative effect of single-agent chemotherapy.
Our explorative analysis of QAPFS is suggested as a model to
assess the trade-offs between prolonged PFS and QoL in this poor
prognostic group of patients. The ongoing GCIG (Gynecologic
Cancer Intergroup) symptom benefit study will hopefully
provide more information on the benefit of chemotherapy on
symptom control and quality of life (Friedlander et al, 2009). In
this patient population with particularly poor prognosis, potential
treatment strategies should also be assessed in terms of their
benefit for QAS. Our analyses may serve as a model for further
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Figure 4. HQOL response proportions at 8 weeks (15% cutoff).
Table 2. Quality-adjusted survival
QA-PFS (n¼221 (93% total population))
Mean PFSa (AUC) Mean utilitya (mixed model) QA-PFSa (SD)
Tamoxifen 13.04 0.61 8.01 (0.939)
Chemotherapy 17.34 0.56 9.76 (0.70)
Diff (TamoxifenChemotherapy) 4.30 0.05 1.75
95% CI (8.54,  1.41) (0.01, 0.09) ( 4.35 0.25)
P 0.02 0.01 0.14
Abbreviations: AUC¼ area under the curve; QA-PFS¼quality-adjusted progression-free survival.
aAnalysis based on 1000 bootstrap replications.
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research on QAS estimates. Selection of patients based on
molecular profiling may hopefully allow us in the future to better
tailor management and ultimately improve survival in patients
with PROC.
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